Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.42 |
| ▸ | APAF1 | O14727 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.41 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12807323 | 0.84 | HCAR2 (0.46) | HCAR2KMT2ACYP1A2PKMCYP2D6 | |
| SCHEMBL2783556 | 0.84 | ESR1 (0.45) | KMT2ACYP1A2GAACYP2C9PKM | |
| SCHEMBL2784263 | 0.84 | ESR1 (0.45) | KMT2ACYP1A2GAACYP2C9PKM | |
| SCHEMBL187761 | 0.83 | KMT2A (0.47) | HCAR2KMT2ACYP1A2GAACYP2C9 | |
| SCHEMBL16672749 | 0.82 | KMT2A (0.58) | HCAR2KMT2ALMNAPTGS1PTGS2 | |
| SCHEMBL12807282 | 0.81 | HCAR2 (0.44) | HCAR2KMT2AGAAFFAR1 | |
| SCHEMBL2000460 | 0.80 | CYP2D6 (0.48) | HCAR2KMT2ACYP2D6SRCLMNA | |
| SCHEMBL2828624 | 0.80 | KMT2A (0.44) | HCAR2KMT2ACYP1A2GAACYP2C9 | |
| SCHEMBL16672758 | 0.80 | L3MBTL1 (0.54) | HCAR2KMT2AGAACYP2D6LMNA | |
| SCHEMBL16673423 | 0.80 | MMP8 (0.51) | KMT2ACYP1A2GAACYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2869389-B1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTIC SOLUTION CELL USING SAME | MITSUBISHI CHEM CORP (JP) | 2019-11-13 | — | — | EP | disclosed |
| US-10320030-B2 | Nonaqueous electrolyte solution and nonaqueous electrolyte battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2019-06-11 | — | — | US | disclosed |
| US-20150140448-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2015-05-21 | — | — | US | disclosed |
| EP-2869389-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTIC SOLUTION CELL USING SAME | Mitsubishi Chemical Corporation (JP) | 2015-05-06 | — | — | EP | disclosed |
| US-20140107135-A1 | PYRIMIDINONE INHIBITORS OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 | AUSPEX PHARMACEUTICALS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| EP-1404309-A1 | A PHARMACEUTICAL COMBINATION COMPRISING EITHER (S)-2-ETHOXY-3- 4-(2- 4-METHANE SULFONYL OXYPHENYL ETHOXY) PHENYL] PROPANOIC ACID OR 3- 4- 2- (4-TERT-BUTOXY CARBONYL AMINOPHENYL) ETHOXY] PHENYL -(S)-2-ETHOXY PROPANOIC ACID AND A BIGUANIDE DRUG | AstraZeneca AB (SE) | 2004-04-07 | — | — | EP | disclosed |
| EP-1401485-A1 | A PHARMACEUTICAL COMBINATION COMPRISING EITHER (S)-2-ETHOXY-3 4-(2- 4-METHANE SULFONYL OXYPHENYL ETHOXY)PHENYL] PROPANOIC ACID OR 3- 4- 2- (4-TERT-BUTOXY CARBONYLAMINO PHENYL) ETHOXY] PHENYL -(S)-2-ETHOXY PROPANOIC ACID AND INSULIN | AstraZeneca AB (SE) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107135-A1 | PYRIMIDINONE INHIBITORS OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 | PLA2G1B, PLA2G4A, PLA2G4B | HCAR2 1125/4885KMT2A 1547/4885CYP1A2 892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.